Overview

Extension of BPS-MR-PAH-203 in Pulmonary Arterial Hypertension (PAH) Patients

Status:
Completed
Trial end date:
2013-11-30
Target enrollment:
Participant gender:
Summary
This is an open-label study for patients who participated in the BPS-MR-PAH-203 study and have volunteered to continue treatment for PAH with Beraprost Sodium Modified Release (BPS-MR) tablets.
Phase:
Phase 2
Details
Lead Sponsor:
Lung Biotechnology PBC
Treatments:
Beraprost
Epoprostenol